RTW Investments LP lowered its position in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 65.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,113,002 shares of the company's stock after selling 2,148,494 shares during the quarter. RTW Investments LP owned approximately 2.51% of ESSA Pharma worth $1,992,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new stake in ESSA Pharma during the 4th quarter worth about $47,000. Bank of America Corp DE grew its holdings in ESSA Pharma by 10,153,775.0% during the 4th quarter. Bank of America Corp DE now owns 812,310 shares of the company's stock worth $1,454,000 after acquiring an additional 812,302 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in ESSA Pharma by 269.9% during the 4th quarter. BNP Paribas Financial Markets now owns 164,595 shares of the company's stock worth $295,000 after acquiring an additional 120,100 shares during the last quarter. Jane Street Group LLC bought a new position in ESSA Pharma in the 4th quarter valued at $82,000. Finally, Vazirani Asset Management LLC bought a new position in ESSA Pharma in the 4th quarter valued at $90,000. Institutional investors and hedge funds own 75.12% of the company's stock.
ESSA Pharma Trading Down 0.6%
Shares of EPIX traded down $0.01 during trading hours on Monday, hitting $1.70. 62,605 shares of the stock traded hands, compared to its average volume of 338,260. The business has a fifty day moving average of $1.65 and a 200-day moving average of $1.69. The firm has a market capitalization of $75.46 million, a PE ratio of -2.46 and a beta of 1.69. ESSA Pharma Inc. has a 1-year low of $1.40 and a 1-year high of $7.88.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last released its earnings results on Thursday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. As a group, equities research analysts expect that ESSA Pharma Inc. will post -0.42 earnings per share for the current fiscal year.
About ESSA Pharma
(
Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
See Also
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
